Carnegie Investment Counsel Has $2.88 Million Position in CVS Health Corporation $CVS

Carnegie Investment Counsel cut its stake in shares of CVS Health Corporation (NYSE:CVS) by 17.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,061 shares of the pharmacy operator’s stock after selling 8,634 shares during the quarter. Carnegie Investment Counsel’s holdings in CVS Health were worth $2,877,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Sei Investments Co. lifted its holdings in CVS Health by 17.4% during the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after purchasing an additional 134,535 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after buying an additional 13,329 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in shares of CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after buying an additional 7,588 shares in the last quarter. HUB Investment Partners LLC increased its holdings in shares of CVS Health by 25.0% during the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after buying an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of CVS Health by 8.0% in the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after acquiring an additional 119,439 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Activity

In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last three months. Company insiders own 0.85% of the company’s stock.

CVS Health Stock Down 0.0%

NYSE:CVS opened at $104.15 on Monday. The stock’s fifty day moving average price is $96.91 and its two-hundred day moving average price is $84.21. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $106.15. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market cap of $132.88 billion, a price-to-earnings ratio of 45.88, a P/E/G ratio of 1.02 and a beta of 0.61.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s payout ratio is currently 117.18%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on CVS shares. Bank of America increased their price target on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Morgan Stanley lifted their price objective on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Wells Fargo & Company boosted their price objective on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research note on Monday, June 1st. Finally, DA Davidson lifted their price target on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.84.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health declared a quarterly dividend of $0.665 per share, reinforcing its shareholder-return policy and signaling management confidence in cash generation. CVS Health declares quarterly dividend
• Positive Sentiment: Coverage around CVS highlighted the company as a likely beneficiary of managed-care consolidation, with commentary that Aetna is handling medical costs and that CVS is well positioned as Walgreens weakens. Cramer’s Stop Trading: CVS Health
• Neutral Sentiment: A CVS executive, Ali Keshavarz, was appointed to the board of Choice Hotels; this is notable for the executive’s profile but does not appear to have a direct operational impact on CVS. Choice Hotels (CHH) Appoints CVS Data Chief To Board As Index Changes Hit
• Negative Sentiment: CVS and Omnicare agreed to a $440 million settlement with the U.S. Department of Justice to resolve improper billing allegations, which creates a large one-time legal cost and keeps regulatory pressure on the company. CVS, Omnicare ink $440M deal with DoJ to resolve improper billing case
• Negative Sentiment: CVS also settled a separate $36.5 million case tied to false Medicaid insulin claims, adding to the legal overhang and reinforcing concerns about compliance risks. CVS settles for $36.5M over false Medicaid insulin claims, Minnesota recovers $400K

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.